Altimmune's pemvidutide shows strong Phase IIb results for MASH, promising Phase III prospects. Read here for more analysis on ALT stock.
T1 Energy has signed a three-year deal to supply a minimum of 900 MW of US-made modules while scaling its Austin cell fab to ...
Introduction This article outlines the research protocol for a multicentre, randomised, controlled study designed to evaluate the therapeutic effect of a modified olfactory training (MOT) based on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback